Literature DB >> 22965382

In vitro osteoclast-like and osteoblast cells' response to electrospun calcium phosphate biphasic candidate scaffolds for bone tissue engineering.

I Wepener1, W Richter, D van Papendorp, A M Joubert.   

Abstract

Successful long term bone replacement and repair remain a challenge today. Nanotechnology has made it possible to alter materials' characteristics and therefore possibly improve on the material itself. In this study, biphasic hydroxyapatite/β-tricalcium phosphate nanobioceramic scaffolds were prepared by the electrospinning technique in order to mimic the extracellular matrix. Scaffolds were characterised by scanning electron microscopy (SEM) and attenuated total reflectance-fourier transform infrared. Osteoblasts as well as monocytes that were differentiated into osteoclast-like cells, were cultured separately on the biphasic bioceramic scaffolds for up to 6 days and the proliferation, adhesion and cellular response were determined using lactate dehydrogenase cytotoxicity assay, nucleus and cytoskeleton dynamics, analysis of the cell cycle progression, measurement of the mitochondrial membrane potential and the detection of phosphatidylserine expression. SEM analysis of the biphasic bioceramic scaffolds revealed nanofibers spun in a mesh-like scaffold. Results indicate that the biphasic bioceramic electrospun scaffolds are biocompatible and have no significant negative effects on either osteoblasts or osteoclast-like cells in vitro.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22965382     DOI: 10.1007/s10856-012-4751-y

Source DB:  PubMed          Journal:  J Mater Sci Mater Med        ISSN: 0957-4530            Impact factor:   3.896


  29 in total

1.  Apatite-formation ability--predictor of "bioactivity"?

Authors:  Haobo Pan; Xiaoli Zhao; Brian W Darvell; William W Lu
Journal:  Acta Biomater       Date:  2010-05-21       Impact factor: 8.947

Review 2.  Methods for the assessment of mitochondrial membrane permeabilization in apoptosis.

Authors:  Lorenzo Galluzzi; Naoufal Zamzami; Thibault de La Motte Rouge; Christophe Lemaire; Catherine Brenner; Guido Kroemer
Journal:  Apoptosis       Date:  2007-05       Impact factor: 4.677

3.  Bioactive silica-collagen composite xerogels modified by calcium phosphate phases with adjustable mechanical properties for bone replacement.

Authors:  Sascha Heinemann; Christiane Heinemann; Ricardo Bernhardt; Antje Reinstorf; Berthold Nies; Michael Meyer; Hartmut Worch; Thomas Hanke
Journal:  Acta Biomater       Date:  2009-02-28       Impact factor: 8.947

Review 4.  Nanosized and nanocrystalline calcium orthophosphates.

Authors:  Sergey V Dorozhkin
Journal:  Acta Biomater       Date:  2009-10-25       Impact factor: 8.947

Review 5.  The osteoclast--what's new?

Authors:  Nicolas A Athanasou
Journal:  Skeletal Radiol       Date:  2011-08-17       Impact factor: 2.199

6.  Novel hybrid scaffolds for the cultivation of osteoblast cells.

Authors:  Hilal Turkoglu Sasmazel
Journal:  Int J Biol Macromol       Date:  2011-08-04       Impact factor: 6.953

7.  Twenty-first century challenges for biomaterials.

Authors:  Larry L Hench; Ian Thompson
Journal:  J R Soc Interface       Date:  2010-05-19       Impact factor: 4.118

Review 8.  Bioceramics of calcium orthophosphates.

Authors:  Sergey V Dorozhkin
Journal:  Biomaterials       Date:  2009-12-07       Impact factor: 12.479

9.  The induction of bone formation by coral-derived calcium carbonate/hydroxyapatite constructs.

Authors:  Ugo Ripamonti; Jean Crooks; Lerato Khoali; Laura Roden
Journal:  Biomaterials       Date:  2008-12-09       Impact factor: 12.479

10.  Resorbability of bone substitute biomaterials by human osteoclasts.

Authors:  Arndt F Schilling; Wolfgang Linhart; Sandra Filke; Matthias Gebauer; Thorsten Schinke; Johannes M Rueger; Michael Amling
Journal:  Biomaterials       Date:  2004-08       Impact factor: 12.479

View more
  1 in total

Review 1.  Nanostructured platforms for the sustained and local delivery of antibiotics in the treatment of osteomyelitis.

Authors:  Vuk Uskokovic
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2015       Impact factor: 4.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.